A Phase 1 interventional study of Prazosin HCl 2mg and Prazosin HCl 1 mg in Hypertension and Heart Failure, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-12.
Sponsored by Pfizer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hypertension by Pfizer — none open to participants now, none under way, none of them phase 3. Hypertension · Pfizer.
Among the 16 studies in Hypertension by Pfizer, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2021, is one of 2 in phase 1, and was the 16th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 16 studies in Hypertension by Pfizer is open now. The open studies under Hypertension, anywhere →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 134 across the 11 interventional studies, 472 across the 4 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Hypertension by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prazosin hydrochloride (HCl) is an oral anti-hypertensive indicated for the treatment of primary and secondary hypertension and heart failure. Pfizer Inc. is the marketing authorization holder for prazosin HCl oral capsules and intended to transfer drug product manufacturing operations from Pfizer, Barceloneta Puerto Rico to Pfizer Pharmaceutical, Ascoli, Italy. To support the manufacturer site transfer and process changes, this bioequivalence (BE) study is being conducted.
This study will be a 2 Cohort, open-label, randomized, single dose study in healthy adult male and/or female participants. Cohort 1 will be crossover with 3 treatments, 3 periods, 6 sequences. Cohort 2 will be crossover with 2 treatments, 2 periods, 2 sequences. Primary objective of this study is demonstrate bioequivalence between prazosin HCl 1, 2 and 5 mg capsules manufactured at Ascoli versus prazosin HCl 2 and 5 mg capsules manufactured at Barceloneta under fasting conditions in healthy adult participants. Approximately 36 participants will be enrolled in each Cohort 1 and Cohort 2.
Pharmacokinetic and statistical analysis will be performed for prazosin. Data from 2 Cohorts will be analyzed separately. The PK parameters area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast), and from time zero extrapolated to infinite time (AUCinf), maximum plasma concentration (Cmax), time to first occurrence of Cmax (Tmax), and terminal phase elimination half-life (t½) will be summarized descriptively by analyte and treatment.
For primary objective, bioequivalence of the Test treatment relative to Reference treatment will be concluded if the 90% confidence intervals (CI) for the ratio of adjusted geometric means of Test treatments relative to Reference treatment for AUCinf (if data permit), AUClast and Cmax, fall wholly within (80%, 125%).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One 2 mg capsule manufactured at the current site, Barceloneta
Drug: Prazosin HCl 2mg
One 2 mg capsule manufactured at the proposed site (Ascoli)
Drug: Prazosin HCl 2mg
Two 1 mg capsule manufactured at the proposed site, Ascoli
Drug: Prazosin HCl 1 mg
One 5 mg capsule manufactured at the current site, Barceloneta
Drug: Prazosin HCl 5 mg
One 5 mg capsule manufactured at the proposed site, Ascoli
Drug: Prazosin HCl 5 mg
Prazosin HCL 1 X 2 mg capsule.
Also known as: Minipress 2 mg capsule.
Prazosin HCl 2 X 1 mg capsule.
Also known as: Minipress 1 mg capsule.
Prazosin HCL 1 X 5 mg capsule.
Also known as: Minipress 5 mg capsule.
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Prazosin
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period
Maximum Observed Plasma Concentration (Cmax) of Prazosin
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period
Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prazosin
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Prazosin
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period
Plasma Decay Half-Life (t1/2) of Prazosin
Plasma terminal elimination half-life of Prazosin was measured.
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of each period
Number of Participants With Adverse Events (AEs) According to Seriousness
Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product or medical device, without regard to causality. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). Time frame for safety monitoring was from screening to Follow-Up Completion (Day 35 after the last dose administration of the last period), and the actual time frame might vary according to the number of doses received and the length of washing period of each dose for each participant.
Time frame: Time frame varied from 20 days to 94 days for cohort 1, and 8 days to 73 days for cohort 2.
| Milestone | Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 1x5 mg (Barceloneta) => Prazosin HCL 1x5 mg (Ascoli) | Prazosin HCL 1x5 mg (Ascoli) => Prazosin HCL 1x5 mg (Barceloneta) |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 18 | 18 |
| Completed | 6 | 6 | 6 | 6 | 6 | 6 | 18 | 18 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 1x5 mg (Barceloneta) => Prazosin HCL 1x5 mg (Ascoli) | Prazosin HCL 1x5 mg (Ascoli) => Prazosin HCL 1x5 mg (Barceloneta) |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 18 | 18 |
| Completed | 5 | 5 | 5 | 5 | 6 | 5 | 16 | 15 |
| Not completed | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 3 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 3 |
| Milestone | Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) => Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 2x1 mg (Ascoli) => Prazosin HCL 1x2 mg (Ascoli) => Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 1x5 mg (Barceloneta) => Prazosin HCL 1x5 mg (Ascoli) | Prazosin HCL 1x5 mg (Ascoli) => Prazosin HCL 1x5 mg (Barceloneta) |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 18 | 18 |
| Completed | 5 | 5 | 5 | 4 | 6 | 5 | 16 | 15 |
| Not completed | 1 | 1 | 1 | 2 | 0 | 1 | 2 | 3 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 3 |
| nanogram*hour per milliliter (ng*hr/mL) | Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x5 mg (Barceloneta) | Prazosin HCL 1x5 mg (Ascoli) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Prazosin | 85.77 ± 34 | 88.37 ± 31 | 92.39 ± 34 | 192.3 ± 147 | 252.2 ± 37 |
| nanogram per milliliter (ng/mL) | Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x5 mg (Barceloneta) | Prazosin HCL 1x5 mg (Ascoli) |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Prazosin | 14.82 ± 49 | 17.04 ± 36 | 19.20 ± 37 | 30.91 ± 143 | 38.69 ± 132 |
| ng*hr/mL | Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x5 mg (Barceloneta) | Prazosin HCL 1x5 mg (Ascoli) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prazosin | 89.10 ± 33 | 90.28 ± 31 | 93.01 ± 31 | 236.7 ± 37 | 259.0 ± 37 |
| hr | Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x5 mg (Barceloneta) | Prazosin HCL 1x5 mg (Ascoli) |
|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Prazosin | 2.00 (0.750 to 6.03) | 2.00 (0.500 to 4.00) | 1.50 (0.500 to 3.50) | 2.50 (1.00 to 8.03) | 2.00 (0.500 to 8.00) |
Plasma terminal elimination half-life of Prazosin was measured.
| hr | Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x5 mg (Barceloneta) | Prazosin HCL 1x5 mg (Ascoli) |
|---|---|---|---|---|---|
| Plasma Decay Half-Life (t1/2) of Prazosin | 5.330 ± 1.2494 | 5.236 ± 1.0565 | 5.022 ± 1.1691 | 4.676 ± 1.1422 | 4.775 ± 1.1594 |
Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product or medical device, without regard to causality. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). Time frame for safety monitoring was from screening to Follow-Up Completion (Day 35 after the last dose administration of the last period), and the actual time frame might vary according to the number of doses received and the length of washing period of each dose for each participant.
| Participants | Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x5 mg (Barceloneta) | Prazosin HCL 1x5 mg (Ascoli) |
|---|---|---|---|---|---|
| Participants with non-serious AEs (all-causality) | 10 | 5 | 6 | 17 | 18 |
| Participants with non-serious AEs (treatment-related) | 9 | 4 | 5 | 16 | 18 |
| Participants with SAEs (all-causality) | 1 | 0 | 0 | 0 | 0 |
| Participants with SAEs (treatment-related) | 0 | 0 | 0 | 0 | 0 |
Collected over Time frame for safety monitoring was from screening to Follow-Up Completion (Day 35 after the last dose administration of the last period), and the actual time frame might vary according to the number of doses received and the length of washing period of each dose for each participant. Actual time frame varied from 20 days to 94 days for cohort 1, and 8 days to 73 days for cohort 2.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prazosin HCL 1x2 mg (Barceloneta) | 1/34 (2.9%) | 1/34 (2.9%) | 8/34 (23.5%) |
| Prazosin HCL 1x2 mg (Ascoli) | 0/33 (0%) | 0/33 (0%) | 4/33 (12.1%) |
| Prazosin HCL 2x1 mg (Ascoli) | 0/33 (0%) | 0/33 (0%) | 5/33 (15.2%) |
| Prazosin HCL 1x5 mg (Barceloneta) | 0/33 (0%) | 0/33 (0%) | 16/33 (48.5%) |
| Prazosin HCL 1x5 mg (Ascoli) | 0/34 (0%) | 0/34 (0%) | 18/34 (52.9%) |
| Event | Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x5 mg (Barceloneta) | Prazosin HCL 1x5 mg (Ascoli) |
|---|---|---|---|---|---|
| Road traffic accidentInjury, poisoning and procedural complications | 1/34 | 0/33 | 0/33 | 0/33 | 0/34 |
| Event | Prazosin HCL 1x2 mg (Barceloneta) | Prazosin HCL 1x2 mg (Ascoli) | Prazosin HCL 2x1 mg (Ascoli) | Prazosin HCL 1x5 mg (Barceloneta) | Prazosin HCL 1x5 mg (Ascoli) |
|---|---|---|---|---|---|
| DizzinessNervous system disorders | 0/34 | 0/33 | 0/33 | 9/33 | 7/34 |
| NauseaGastrointestinal disorders | 2/34 | 1/33 | 1/33 | 7/33 | 9/34 |
| HeadacheNervous system disorders | 2/34 | 2/33 | 2/33 | 3/33 | 5/34 |
| Orthostatic hypotensionVascular disorders | 4/34 | 1/33 | 2/33 | 3/33 | 2/34 |
| TachycardiaCardiac disorders | 0/34 | 0/33 | 0/33 | 1/33 | 4/34 |
| SomnolenceNervous system disorders | 0/34 | 0/33 | 0/33 | 0/33 | 2/34 |
| Age, Customized(Participants) | Cohort 1: Male | Cohort 1: Female | Cohort 2: Male | Cohort 2: Female | Total |
|---|---|---|---|---|---|
| <18 years | 0 | 0 | 0 | 0 | 0 |
| 18-44 years | 16 | 7 | 18 | 10 | 51 |
| 45-64 years | 8 | 5 | 2 | 6 | 21 |
| ≥65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1: Male | Cohort 1: Female | Cohort 2: Male | Cohort 2: Female | Total |
|---|---|---|---|---|---|
| Female | 0 | 12 | 0 | 16 | 28 |
| Male | 24 | 0 | 20 | 0 | 44 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Male | Cohort 1: Female | Cohort 2: Male | Cohort 2: Female | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 4 | 8 | 9 | 32 |
| Not Hispanic or Latino | 13 | 8 | 12 | 7 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Male | Cohort 1: Female | Cohort 2: Male | Cohort 2: Female | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 8 | 1 | 5 | 4 | 18 |
| White | 16 | 8 | 13 | 12 | 49 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Sep 2021 to primary completion in Feb 2022, 4 months.
Results were first posted in Jul 2024, 2 years 4 months after primary completion.
Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 4 months is above that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prazosin